165 related articles for article (PubMed ID: 19759551)
1. Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.
Jovanovic B; Egyhazi S; Eskandarpour M; Ghiorzo P; Palmer JM; Bianchi Scarrà G; Hayward NK; Hansson J
J Invest Dermatol; 2010 Feb; 130(2):618-20. PubMed ID: 19759551
[No Abstract] [Full Text] [Related]
2. Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.
Zebary A; Omholt K; van Doorn R; Ghiorzo P; Harbst K; Hertzman Johansson C; Höiom V; Jönsson G; Pjanova D; Puig S; Scarra GB; Harland M; Olsson H; Egyhazi Brage S; Palmer J; Kanter-Lewensohn L; Vassilaki I; Hayward NK; Newton-Bishop J; Gruis NA; Hansson J;
J Invest Dermatol; 2014 Jan; 134(1):287-290. PubMed ID: 23771122
[No Abstract] [Full Text] [Related]
3. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.
Daniotti M; Ferrari A; Frigerio S; Casieri P; Miselli F; Zucca E; Collini P; Della Torre G; Manoukian S; Peissel B; Bono A; Santinami M; Parmiani G; Rivoltini L; Pilotti S; Rodolfo M
J Invest Dermatol; 2009 Jul; 129(7):1759-68. PubMed ID: 19158841
[TBL] [Abstract][Full Text] [Related]
4. Progression of NRAS and BRAF mutations in cutaneous melanoma.
Rosso R; Romagosa Y; Kirsner RS
J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
[No Abstract] [Full Text] [Related]
5. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
6. Absence of germline epimutation of the CDKN2A gene in familial melanoma.
van Doorn R; Zoutman WH; Gruis NA
J Invest Dermatol; 2009 Mar; 129(3):781-4. PubMed ID: 18818678
[No Abstract] [Full Text] [Related]
7. Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.
Casula M; Muggiano A; Cossu A; Budroni M; Caracò C; Ascierto PA; Pagani E; Stanganelli I; Canzanella S; Sini M; Palomba G; ; Palmieri G
BMC Cancer; 2009 Oct; 9():352. PubMed ID: 19799798
[TBL] [Abstract][Full Text] [Related]
8. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.
Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J
J Natl Cancer Inst; 2003 Jun; 95(11):790-8. PubMed ID: 12783933
[TBL] [Abstract][Full Text] [Related]
9. Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients.
Vergani E; Frigerio S; Dugo M; Devecchi A; Feltrin E; De Cecco L; Vallacchi V; Cossa M; Di Guardo L; Manoukian S; Peissel B; Ferrari A; Gallino G; Maurichi A; Rivoltini L; Sensi M; Rodolfo M
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573422
[TBL] [Abstract][Full Text] [Related]
10. Germline CDKN2A/p16 mutations are rare in multiple primary and familial malignant melanoma in German patients.
Lukowsky A; Schäfer-Hesterberg G; Sterry W; Voit C
J Dermatol Sci; 2008 Feb; 49(2):163-5. PubMed ID: 17890059
[No Abstract] [Full Text] [Related]
11. The pathway ahead in melanoma trials.
Miller AJ; Markovic SN; Haluska P
Oncology (Williston Park); 2009 May; 23(6):496, 498, 500. PubMed ID: 19544690
[No Abstract] [Full Text] [Related]
12. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
[TBL] [Abstract][Full Text] [Related]
13. Occurrence of ocular melanoma thirteen years after skin melanoma: two separate primaries or metastatic disease? A case solved with NRAS and CDKN2A (INK4A-ARF) mutational analysis.
Küsters-Vandevelde HV; Keunen JE; Wesseling P; Verdijk MA; Ligtenberg MJ; Blokx WA
Virchows Arch; 2008 Mar; 452(3):331-6. PubMed ID: 18205010
[TBL] [Abstract][Full Text] [Related]
14. Association of CDK4 germline and BRAF somatic mutations in a patient with multiple primary melanomas and BRAF inhibitor resistance.
Governa M; Caprarella E; Dalla Pozza E; Vigato E; Maritan M; Caputo GG; Zannoni M; Rosina P; Elefanti L; Stagni C; Menin C
Melanoma Res; 2015 Oct; 25(5):443-6. PubMed ID: 26110554
[TBL] [Abstract][Full Text] [Related]
15. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
16. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
[TBL] [Abstract][Full Text] [Related]
17. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
18. Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.
Lázár V; Ecsedi S; Szöllosi AG; Tóth R; Vízkeleti L; Rákosy Z; Bégány A; Adány R; Balázs M
Mod Pathol; 2009 Oct; 22(10):1367-78. PubMed ID: 19633643
[TBL] [Abstract][Full Text] [Related]
19. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
20. Melanoma: What do all the mutations mean?
Davis EJ; Johnson DB; Sosman JA; Chandra S
Cancer; 2018 Sep; 124(17):3490-3499. PubMed ID: 29663336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
